CMNDHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 22 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Clearmind Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CMND, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CMND appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 90% of US stocks
Cheaper than 57% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Clearmind Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The independent Data and Safety Monitoring Board unanimously approved Clearmind Medicine Inc. to advance its ongoing FDA-regulated Phase 1/2 clinical trial for alcohol addiction treatment, marking clinical progress for the company.
Why it matters — CMND watchers would care because the board's unanimous approval signals the trial can move forward within the regulatory process.
Clearmind Medicine received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND-100 in patients with Alcohol Use Disorder (AUD), marking a key milestone in the progression of the company's clinical development program.
Why it matters — DSMB approval to advance CMND-100 into AUD patients is a key regulatory milestone in Clearmind's clinical development program that CMND watchers would follow.
Clearmind Medicine announced that its independent Data and Safety Monitoring Board (DSMB) unanimously approved advancing the FDA-regulated Phase I/II clinical trial of CMND-100, its candidate for Alcohol Use Disorder (AUD), to Parts B and C. These parts will evaluate the treatment in patients actively suffering from AUD and in healthy participants, respectively.
Why it matters — This DSMB clearance marks a key milestone in the progression of Clearmind's clinical development program for CMND-100 in AUD treatment.
Clearmind Medicine announced it has signed a non-binding Letter of Intent to acquire a 51% majority stake in a company specializing in EV wireless charging solutions for automated parking systems and autonomous mobile platforms.
Why it matters — This move represents a significant strategic shift for Clearmind, a clinical-stage biotech company, by pursuing a majority stake in an unrelated technology sector.
Clearmind Medicine announced positive safety results from Part A of its Phase I/II clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder. All 24 participants across four ascending-dose cohorts completed treatment as planned per-protocol, demonstrating consistent tolerability.
Why it matters — Positive safety and tolerability data from an early-stage FDA-regulated trial reduces clinical risk for CMND-100, a key pipeline asset for Clearmind.
As at 22 Aug 2026, Clearmind Medicine, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
No analyst covering Clearmind Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMND are extrapolating price history, which says nothing about the business.
Clearmind Medicine, Inc. returned -99.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address underserved health issues.
The most recent item we track (Benzinga, 13 Aug 2026): "Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial". The independent Data and Safety Monitoring Board unanimously approved Clearmind Medicine Inc. to advance its ongoing FDA-regulated Phase 1/2 clinical trial for alcohol addiction treatment, marking clinical progress for the company.
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address underserved health issues. Its primary efforts center on treatments for alcohol use disorder, including the lead candidate CMND-100, which is in an FDA-approved Phase I/IIa clinical trial, and MEAI, a non-hallucinogenic neuroplastogen targeted at obesity, metabolic disorders, compulsive eating, binge drinking, eating disorders, anxiety, depression, and post-traumatic stress disorder. The company also explores intranasal formulations and collaborations to enhance drug delivery for addiction-related and central nervous system conditions. Clearmind Medicine Inc. maintains an extensive intellectual property portfolio comprising 15 patent families with granted and pending patents across multiple jurisdictions. Founded in 2017 and headquartered in Vancouver, Canada, it operates as a key player in the emerging field of psychedelic medicines for mental health and behavioral disorders.
Canada · https://www.clearmindmedicine.com